Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination

Karim Dorgham, Valérie Abadie, Mutsunori Iga, Oliver Hartley, Guy Gorochov, Behazine Combadière

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA + 1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA + CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.

Original languageEnglish
Pages (from-to)3252-3260
Number of pages9
JournalVaccine
Volume26
Issue number26
DOIs
Publication statusPublished - Jun 19 2008

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination'. Together they form a unique fingerprint.

Cite this